A Phase 3 interventional study of Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler and Placebo inhalation powders via ELLIPTA inhaler in Asthma, sponsored by GlaxoSmithKline. Completed at 179 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-08-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 5th largest by enrollment of the 146 interventional ones that give a count, is one of 7 that started in 2015, is one of 35 in phase 3, and was the 110th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,526 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 8th largest by enrollment of the 238 interventional ones that give a count, is one of 12 that started in 2015, is one of 61 in phase 3, and was the 187th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, double-dummy, parallel group, multicenter, non-inferiority study. The study will enroll adult and adolescent asthmatic subjects who are currently receiving mid dose inhaled corticosteroids (ICS) plus long-acting beta2-agonist (LABA) (equivalent to fluticasone propionate [FP]/salmeterol 250/50 microgram [mcg]twice daily [BD]), either via a fixed dose combination product or through separate inhalers. The study consists of a LABA washout period of 5 days and a run-in period of 4 weeks, followed by a treatment period of 24 weeks, and a follow up contact period of one week. The total duration of the study is 30 weeks. Approximately 1461 subjects will be randomized to one of the following three treatments (487 per treatment): fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg once daily (OD) in the evening (PM) via ELLIPTA™ inhaler plus placebo BD via ACCUHALER™/DISKUS™; FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler; FP 250 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler. In addition, all subjects will be supplied with albuterol/salbutamol inhalation aerosol to use as needed to treat acute asthma symptoms. This study will determine if FF/VI 100/25 mcg OD via ELLIPTA inhaler is non-inferior to FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler in adult and adolescent asthmatic subjects already adequately controlled on a twice-daily ICS/LABA.
SERETIDE, ELLIPTA, ACCUHALER, RELVAR, and DISKUS are trademarks of the GlaxoSmithKline Group of Companies.
Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler · Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
Drug: Placebo inhalation powders via ELLIPTA inhaler · Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler
FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
Drug: Placebo inhalation powders via ELLIPTA inhaler · Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
Drug page: Fluticasone
FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the mixed model repeated measures (MMRM) model and least square mean and standard error were calculated. The analysis was performed on ITT Population which comprised of all participants randomized to treatment and who received at least one dose of study medication.
Time frame: Baseline and Week 24
Change From Baseline in PM FEV1 Using Per Protocol (PP) Population
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the MMRM models and least square mean and standard error were calculated. The analysis was performed on PP Population which comprised of all participants in the ITT Population who did not had any full protocol deviations.
Time frame: Baseline and Week 24
Change From Baseline in the Percentage of Rescue-free 24-hour Periods
The number of inhalations of rescue medication used during the day and night were recorded by participants using an electronic diary (e-diary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Change From Baseline in the Percentage of Symptom-free 24-hour Periods
Change from Baseline in the percentage of symptom-free 24 hour period was evaluated. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value.Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)
PEF was measured using an electric flow meter each morning. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20
The ACT was a five-item questionnaire developed as a measure of participant's asthma control. The percentage of participants controlled, defined as having ACT score greater than or equal to 20 at the end of Week 24 were analyzed using logistic regression model with covariates of Baseline ACT score, region, sex, age and treatment group.
Time frame: Week 24
Change From Baseline in PM PEF
PEF was measured using an electric flow meter each evening. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Time frame: Baseline and Weeks 1-24
Eligible participants at screening and run-in visits entered a 24 Week treatment period and were randomized to receive either Fluticasone furoate/Vilanterol (FF/VI) 100/25 micrograms (mcg) or Fluticasone propionate/salmeterol (FP/S) 250/50mcg or only FP 250mcg followed by a follow-up phase. The total duration for study participation was 30 weeks.
| Milestone | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Started | 504 | 501 | 499 |
| Completed | 473 | 476 | 477 |
| Not completed | 31 | 25 | 22 |
| Withdrew: Adverse event | 8 | 3 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 |
| Withdrew: Protocol violation | 3 | 5 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 |
| Withdrew: Physician decision | 4 | 2 | 3 |
| Withdrew: Withdrawal by subject | 15 | 12 | 11 |
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the mixed model repeated measures (MMRM) model and least square mean and standard error were calculated. The analysis was performed on ITT Population which comprised of all participants randomized to treatment and who received at least one dose of study medication.
| Liter (L) | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population | 0.019 ± 0.0107 | 0.000 ± 0.0108 | -0.104 ± 0.0109 |
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the MMRM models and least square mean and standard error were calculated. The analysis was performed on PP Population which comprised of all participants in the ITT Population who did not had any full protocol deviations.
| L | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Change From Baseline in PM FEV1 Using Per Protocol (PP) Population | 0.020 ± 0.0120 | 0.014 ± 0.0120 | -0.099 ± 0.0121 |
The number of inhalations of rescue medication used during the day and night were recorded by participants using an electronic diary (e-diary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
| Percentage of rescue-free 24-hr periods | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Change From Baseline in the Percentage of Rescue-free 24-hour Periods | -3.0 ± 0.62 | -4.2 ± 0.62 | -5.7 ± 0.62 |
Change from Baseline in the percentage of symptom-free 24 hour period was evaluated. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value.Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
| Percentage of symptom-free 24 hour perio | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Change From Baseline in the Percentage of Symptom-free 24-hour Periods | -3.5 ± 0.67 | -4.7 ± 0.67 | -6.2 ± 0.67 |
PEF was measured using an electric flow meter each morning. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
| Liter per minute (L/min) | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF) | 8.9 ± 1.48 | 3.7 ± 1.49 | -12.6 ± 1.49 |
The ACT was a five-item questionnaire developed as a measure of participant's asthma control. The percentage of participants controlled, defined as having ACT score greater than or equal to 20 at the end of Week 24 were analyzed using logistic regression model with covariates of Baseline ACT score, region, sex, age and treatment group.
| Percentage of participants | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20 | 92 | 93 | 91 |
PEF was measured using an electric flow meter each evening. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
| L/min | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Change From Baseline in PM PEF | 5.5 ± 1.55 | 0.5 ± 1.55 | -13.7 ± 1.55 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment until the follow up contact one week after completion of study medication (Up to Week 25).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FF/VI 100/25 mcg Once Daily | 0/504 (0%) | 6/504 (1.2%) | 126/504 (25%) |
| FP/S 250/50 mcg Twice Daily | 0/501 (0%) | 4/501 (0.8%) | 123/501 (24.6%) |
| FP 250 mcg Twice Daily | 0/499 (0%) | 5/499 (1%) | 124/499 (24.8%) |
| Event | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 0/504 | 0/501 | 1/499 |
| Abdominal abscessInfections and infestations | 0/504 | 0/501 | 1/499 |
| Foot fractureInjury, poisoning and procedural complications | 0/504 | 0/501 | 1/499 |
| Joint instabilityMusculoskeletal and connective tissue disorders | 0/504 | 0/501 | 1/499 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/504 | 0/501 | 1/499 |
| HypertensionVascular disorders | 0/504 | 0/501 | 1/499 |
| Large intestine perforationGastrointestinal disorders | 0/504 | 1/501 | 0/499 |
| EpilepsyNervous system disorders | 0/504 | 1/501 | 0/499 |
| Psychotic disorderPsychiatric disorders | 0/504 | 1/501 | 0/499 |
| Vocal cord leukoplakiaRespiratory, thoracic and mediastinal disorders | 0/504 | 1/501 | 0/499 |
| Event | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 61/504 | 67/501 | 57/499 |
| HeadacheNervous system disorders | 41/504 | 37/501 | 40/499 |
| BronchitisInfections and infestations | 20/504 | 10/501 | 13/499 |
| InfluenzaInfections and infestations | 9/504 | 12/501 | 19/499 |
| PharyngitisInfections and infestations | 15/504 | 13/501 | 18/499 |
| Age, Continuous(Participants) | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily | Total |
|---|---|---|---|---|
| Mean | 44.4 ± 16.30 | 43.0 ± 15.20 | 43.0 ± 16.58 | 43.5 ± 16.04 |
| Sex: Female, Male(Participants) | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily | Total |
|---|---|---|---|---|
| Female | 314 | 336 | 314 | 964 |
| Male | 190 | 165 | 185 | 540 |
| Race/Ethnicity, Customized(Participants) | FF/VI 100/25 mcg Once Daily | FP/S 250/50 mcg Twice Daily | FP 250 mcg Twice Daily | Total |
|---|---|---|---|---|
| American Indian or Alaska native | 0 | 0 | 1 | 1 |
| Asian - East Asian Heritage | 8 | 11 | 4 | 23 |
| Asian- Japanese Heritage | 1 | 0 | 0 | 1 |
| Asian- South East Asian Heritage | 1 | 0 | 1 | 2 |
| Black/African American Heritage | 12 | 14 | 17 | 43 |
| White- Arabic/ North African Heritage | 0 | 1 | 2 | 3 |
| White- White/Caucasian/European Heritage | 415 | 407 | 410 | 1232 |
| White- Mixed White Race | 1 | 0 | 0 | 1 |
| African American/ African and White Heritage | 0 | 5 | 0 | 5 |
| American Indian/Alaskan Native and White Heritage | 66 | 62 | 64 | 192 |
| Asian - East Asian and White Heritage | 0 | 1 | 0 | 1 |
Showing the first 100 of 179 sites across 12 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone